RPL17 and neoplasm: Overall, the 10 most cited papers focus on several key areas: immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors), cellular therapies in immunotherapy, and the tumor immune microenvironment and immune evasion mechanisms.